Digital Health in Japan and Korea – Where Is It Heading?

Rise of Innovative Medtech in APAC

India, the Generic Manufacturing Powerhouse, Biosimilar Next?

Tencent-Backed Wedoctor Is Going Public: What Are the Next Steps for Chinese Digital Health Companies?

Hong Kong Exchange: Nurturing China’s Biotech Valley

How COVID-19 is Accelerating Telemedicine Adoption in Asia Pacific

US SARS-CoV-2 Testing Response: What can be learned from South Korea and Germany?

Medtech Geographic Launch Sequences Warrant Reevaluation

Key Trends and Developments in the Chinese Oncology Market

Australian Biotechs and Medtechs: Look to the East

Changes in China: How Can Medtech Companies Succeed? (Part Two)

Changes in China: How Can Medtech Companies Succeed? (Part One)

Better Market Access in China – Government Improves Pricing and Reimbursement Environment

Keytruda, a case study for the improved regulatory environment in China

Improvements in China Drug Registration – Opening the Door to the China Market for Global BioPharma

Health Advances Presentation at ISPOR: An Initial Analysis of the Cost-Based Pricing Revisions in Japan

Health Advances Blog

Category: Asia/APAC Markets

Digital Health in Japan and Korea – Where Is It Heading?

Rise of Innovative Medtech in APAC

India, the Generic Manufacturing Powerhouse, Biosimilar Next?

Tencent-Backed Wedoctor Is Going Public: What Are the Next Steps for Chinese Digital Health Companies?

Hong Kong Exchange: Nurturing China’s Biotech Valley

How COVID-19 is Accelerating Telemedicine Adoption in Asia Pacific

US SARS-CoV-2 Testing Response: What can be learned from South Korea and Germany?

Medtech Geographic Launch Sequences Warrant Reevaluation

Key Trends and Developments in the Chinese Oncology Market

Australian Biotechs and Medtechs: Look to the East

Changes in China: How Can Medtech Companies Succeed? (Part Two)

Changes in China: How Can Medtech Companies Succeed? (Part One)

Better Market Access in China – Government Improves Pricing and Reimbursement Environment

Keytruda, a case study for the improved regulatory environment in China

Improvements in China Drug Registration – Opening the Door to the China Market for Global BioPharma

Health Advances Presentation at ISPOR: An Initial Analysis of the Cost-Based Pricing Revisions in Japan